Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.
Inclusion Criteria:
metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Exclusion Criteria:
clinicaltrials@novonordisk.com(+1) 866-867-7178
Fargo, North Dakota 58104, United States
New Lambton Heights, New South Wales 2305, Australia
Szeged, Csongrád-Csanád 6725, Hungary
Lublin, Lublin Voivodeship 20-049, Poland
Bialystok, Podlaskie Voivodeship 15-879, Poland
Kielce, 25-355, Poland
Timișoara, 300723, Romania
Seoul, 06591, South Korea